Polyreactive antibodies in multidonor-derived immunoglobulin G: Theory and conclusions drawn from experiments

Immunobiology

Volumn 215, Issue 5, 2010, Pages 356-369

  Gronski, Peter ^a   Schridde, C ^b   Försterling, Horst Dieter ^b  

^a CSL BEHRING GMBH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Crossreactivity; Human polyclonal IgG; Multireactivity; Multispecificity; Polyreactivity

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MONOMER;

ANALYTIC METHOD; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD DONOR; CONCENTRATION (PARAMETERS); DIMERIZATION; DISSOCIATION; DRUG SCREENING; HUMAN; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MASS ACTION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PLASMA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

COMPUTER SIMULATION; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; KINETICS; MODELS, CHEMICAL; PROTEIN MULTIMERIZATION;

EID: 77950934315     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.06.015     Document Type: Article

References (48)

1. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 2008, 105:19571-19578.
2. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
3. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 1991, 12:154-159.
4. Basta M., Langlois P.F., Marques M., Frank M.M., Fries L.F. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989, 74:326-333.
5. Basta M., Kirshbom P., Frank M.M., Fries L.F. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 1989, 84:1974-1981.
6. Bayary J., Dasgupta S., Misra N., Ephrem A., Huyen J.P., Delignat S., Hassan G., Caligiuri G., Nicoletti A., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int. Immunopharmacol. 2006, 6:528-534.
7. Bayry J., Bansal K., Kazatchkine M.D., Kaveri S.V. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc. Natl. Acad. Sci. USA 2009, 106:E24.
8. Bazin R., Lemieux R., Tremblay T., St-Amour I. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br. J. Haematol. 2004, 127:90-96.
9. Berger M. Subcutaneous administration of IgG. Immunol. Allergy Clin. N. Am. 2008, 28:779-802.
10. Bossart-Whitaker P., Chang C.Y., Novotny J., Benjamin D.C., Sheriff S. The crystal structure of the antibody N10-staphylococcal nuclease complex at 2.9Å resolution. J. Mol. Biol. 1995, 253:559-575.
11. Calvanico N.J. The humoral immune response in autoimmunity. Dermatol. Clin. 1993, 11:379-389.
12. Casali P., Schettino E.W. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 1996, 210:167-179.
13. Chothia C., Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 1987, 196:901-917.
14. Couthinho A., Kazatchkine M.D., Avrameas S. Natural autoantibodies. Curr. Opin. Immunol. 1995, 7:812-818.
15. Cramer D.V. Natural antibodies and the host immune response to xenografts. Xenotransplantation 2000, 7:83-92.
16. Crow A.R., Song S., Semple J.W., Freedman J., Lazarus A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br. J. Hematol. 2001, 115:679-686.
17. Davies D.R., Cohen G.H. Interactions of protein antigens with antibodies. Proc. Natl. Acad. Sci. USA 1996, 93:7-12.
18. Edwards B.M., Barash S.C., Main S.H., Choi G.H., Minter R., Ullrich S., Williams E., Fu L., Wilton J., Albert V.R., Ruben S.M., Vaughan T.J. The remarkable flexibility of the human antibody repertoire; isolation of over thousand different antibodies to a single protein, BLys. J. Mol. Biol. 2003, 334:103-118.
19. Gear C.W. The numerical integration of ordinary differential equations. Math. Comput. 1967, 21:146-156.
20. Gear C.W. Numerical Initial Value Problems in Ordinary Differential Equations 1971, Prentice-Hall, Inc., Englewood Cliffs, NJ, USA.
21. Gilles J.G., Saint-Remy J.M. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J. Clin. Invest. 1994, 94:1496-1505.
22. Green M.G., Bystryn J.C. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch. Dermatol. 2008, 144:1621-1624.
23. Gronski P. IgG dimers in multidonor-derived immunoglobulins: aspects of generation and function. Curr. Pharm. Des. 2006, 12:181-190.
24. Gronski P., Schridde C., Kanzy E.J. Off-rate and concentration diversity in multidonor-derived dimers of immunoglobulin G. Mol. Immunol. 2007, 44:2528-2540.
25. Jefferis R., Lund J., Pound J.D. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 1998, 163:59-76.
26. Jerne N.K. Towards a network theory of the immune system. Ann. Immunol. 1974, 125C:373-386.
27. Jerne N.K., Cazenave P.A. Recurrent idiotopes and internal images. EMBO J. 1982, 1:243-247.
28. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
29. Kaveri S., Prasad N., Vassilev T., Hurez V., Pashov A., Lacroix-Desmazes M. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult. Scler. 1997, 3:121-128.
30. Lamoureux J., Aubin E., Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg?. Int. Immunol. 2004, 16:929-936.
31. Lemieux R., Bazin R. Autoantibody-induced formation of immune complexes in normal human serum. Curr. Pharm. Des. 2006, 12:173-179.
32. Mariuzza R.A., Phillips S.E., Poljak R.J. The structural basis of antigen-antibody recognition. Annu. Rev. Biophys. Biophys. Chem. 1987, 16:139-159.
33. Miescher S.M., Schaub A., Ghielmetti M., Baumann M., Vogel M., Bolli R., Stadler B. Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin. Ann. N. Y. Acad. Sci. 2005, 1051:582-590.
34. Mylvaganam S.E., Paterson Y., Getzoff E.D. Structural basis for the binding of an anti-cytochrome c antibody to its antigen: crystal structures of FabE8-cytochrome c complex to 1.8Å resolution and FabE8 to 2.26Å resolution. J. Mol. Biol. 1998, 281:301-322.
35. Perelson A.S., Oster G.F. Theoretical studies of clonal selection: minimal antibody repertoire size and reliability of self-non-self discrimination. J. Theor. Biol. 1979, 81:645-670.
36. Ravetch J.V., Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 1998, 16:421-432.
37. Ravetch J., Anthony R., Wermeling F., Karlsson M. Reply to Bayry et al.: The anti-inflammatory activity of sialylated IgG Fcs. Proc. Natl. Acad. Sci. USA 2009, 106:E25.
38. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
39. Schaub A., Wymann S., Heller M., Ghielmetti M., Beleznay Z., Stadler B.M., Bolli R., Miescher S.M. Self-reactivity in the dimeric intravenous immunoglobulin fraction. Ann. N. Y. Acad. Sci. 2007, 1110:681-693.
40. Tankersley D.L., Preston M.S., Finlayson J.S. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol. Immunol. 1988, 25:41-48.
41. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., Haas M., Winkel J.G.J., Hack C.E., Bleeker W.K. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the IgG dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099.
42. Tha-In T., Bayry J., Metselaar H.J., Kaveri S.V., Kwekkeboom J. Modulation of cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008, 29:608-615.
43. Tulip W.R., Varghese J.N., Laver W.G., Webster R.G., Colman P.M. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 1992, 227:122-148.
44. Doorn P.A., Rossi F., Brand A., Lint M., Vermeulen M., Kazatchkine M.D. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 1990, 29:57-64.
45. Viard I., Wehrli R., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J.H., Tschopp J., French L.E. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
46. Ward E.S., Ghetie V. The effector functions of immunoglobulins: implications for therapy. Ther. Immunol. 1995, 2:77-94.
47. Wymann S., Ghielmetti M., Schaub A., Baumann M.J., Stadler B.M., Bolli R., Miescher S.M. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens. Mol. Immunol. 2008, 45:2621-2628.
48. Zhou Z.H., Tzioufas A.G., Notkins A.L. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J. Autoimmun. 2007, 29:219-228.